Case Report: Hypertriglyceridemia-Induced Pancreatitis after Lenvatinib and Pembrolizumab Use
Introduction: Lenvatinib and Pembrolizumab together are used as a chemotherapy regimen for patients with metastatic endometrial carcinoma. Lenvatinib is a vascular endothelial growth factor (VEGF) receptor inhibitor, fibroblast growth factor inhibitor and an inhibitor that acts on platelet derived g...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2024-02-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://beta.karger.com/Article/FullText/533904 |
| _version_ | 1797253750923984896 |
|---|---|
| author | Kinza Sultan Ziad Khan Siamak Saadat |
| author_facet | Kinza Sultan Ziad Khan Siamak Saadat |
| author_sort | Kinza Sultan |
| collection | DOAJ |
| description | Introduction: Lenvatinib and Pembrolizumab together are used as a chemotherapy regimen for patients with metastatic endometrial carcinoma. Lenvatinib is a vascular endothelial growth factor (VEGF) receptor inhibitor, fibroblast growth factor inhibitor and an inhibitor that acts on platelet derived growth factor receptor alpha, ret oncogene and c-KIT oncogene. Pembrolizumab is an immune checkpoint inhibitor that acts against programmed-death one (PD-1) receptors and programmed-death ligand one (PD-L1) receptors. In combination, this regimen has proven to be efficacious in the setting of advanced endometrial carcinoma, but this must be weighed against its’ side effect profile, most specifically their individual side effects. Pembrolizumab has been associated with pancreatitis. Lenvatinib has been associated with hypertriglyceridemia. However, little has been published with hypertriglyceridemia-induced pancreatitis in the setting of the combination of Lenvatinib and Pembrolizumab and its’ management. Case Presentation: This case presentation discusses a 57-year-old female with history of stage IV uterine cancer with metastasis to the liver status post total abdominal hysterectomy/bilateral salpingo-oophrectomy (on Lenvatinib 8 mg PO daily/Pembrolizumab 200 mg IV every three weeks) presenting with epigastric pain, nausea, vomiting and decreased appetite; her symptoms were due to hypertriglyceridemia-induced pancreatitis with CT findings consistent with pancreatitis as well as a serum lipase of 1,508, and serum triglyceride level of 2,052; she was treated with IV insulin, resulting in resolution of her hypertriglyceridemia-induced pancreatitis. Conclusion: This case demonstrates a unique presentation of the hypertriglyceridemia induced pancreatitis in the setting of Lenvatinib and Pembrolizumab use and the need for future research to better understand the pathophysiology of the pancreatitis induced by this chemotherapy regimen. |
| first_indexed | 2024-03-07T19:39:15Z |
| format | Article |
| id | doaj.art-0b79059c4306496c843364e08af9804b |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-04-24T21:39:02Z |
| publishDate | 2024-02-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-0b79059c4306496c843364e08af9804b2024-03-21T08:27:29ZengKarger PublishersCase Reports in Oncology1662-65752024-02-0117131131610.1159/000533904533904Case Report: Hypertriglyceridemia-Induced Pancreatitis after Lenvatinib and Pembrolizumab UseKinza Sultan0Ziad Khan1Siamak Saadat2Internal Medicine, Arrowhead Regional Medical Center, Colton, CA, USAHematology-Oncology, Arrowhead Regional Medical Center, Colton, CA, USAHematology-Oncology, Arrowhead Regional Medical Center, Colton, CA, USAIntroduction: Lenvatinib and Pembrolizumab together are used as a chemotherapy regimen for patients with metastatic endometrial carcinoma. Lenvatinib is a vascular endothelial growth factor (VEGF) receptor inhibitor, fibroblast growth factor inhibitor and an inhibitor that acts on platelet derived growth factor receptor alpha, ret oncogene and c-KIT oncogene. Pembrolizumab is an immune checkpoint inhibitor that acts against programmed-death one (PD-1) receptors and programmed-death ligand one (PD-L1) receptors. In combination, this regimen has proven to be efficacious in the setting of advanced endometrial carcinoma, but this must be weighed against its’ side effect profile, most specifically their individual side effects. Pembrolizumab has been associated with pancreatitis. Lenvatinib has been associated with hypertriglyceridemia. However, little has been published with hypertriglyceridemia-induced pancreatitis in the setting of the combination of Lenvatinib and Pembrolizumab and its’ management. Case Presentation: This case presentation discusses a 57-year-old female with history of stage IV uterine cancer with metastasis to the liver status post total abdominal hysterectomy/bilateral salpingo-oophrectomy (on Lenvatinib 8 mg PO daily/Pembrolizumab 200 mg IV every three weeks) presenting with epigastric pain, nausea, vomiting and decreased appetite; her symptoms were due to hypertriglyceridemia-induced pancreatitis with CT findings consistent with pancreatitis as well as a serum lipase of 1,508, and serum triglyceride level of 2,052; she was treated with IV insulin, resulting in resolution of her hypertriglyceridemia-induced pancreatitis. Conclusion: This case demonstrates a unique presentation of the hypertriglyceridemia induced pancreatitis in the setting of Lenvatinib and Pembrolizumab use and the need for future research to better understand the pathophysiology of the pancreatitis induced by this chemotherapy regimen.https://beta.karger.com/Article/FullText/533904hypertriglyceridemia-induced pancreatitisendometrial carcinomacase report |
| spellingShingle | Kinza Sultan Ziad Khan Siamak Saadat Case Report: Hypertriglyceridemia-Induced Pancreatitis after Lenvatinib and Pembrolizumab Use Case Reports in Oncology hypertriglyceridemia-induced pancreatitis endometrial carcinoma case report |
| title | Case Report: Hypertriglyceridemia-Induced Pancreatitis after Lenvatinib and Pembrolizumab Use |
| title_full | Case Report: Hypertriglyceridemia-Induced Pancreatitis after Lenvatinib and Pembrolizumab Use |
| title_fullStr | Case Report: Hypertriglyceridemia-Induced Pancreatitis after Lenvatinib and Pembrolizumab Use |
| title_full_unstemmed | Case Report: Hypertriglyceridemia-Induced Pancreatitis after Lenvatinib and Pembrolizumab Use |
| title_short | Case Report: Hypertriglyceridemia-Induced Pancreatitis after Lenvatinib and Pembrolizumab Use |
| title_sort | case report hypertriglyceridemia induced pancreatitis after lenvatinib and pembrolizumab use |
| topic | hypertriglyceridemia-induced pancreatitis endometrial carcinoma case report |
| url | https://beta.karger.com/Article/FullText/533904 |
| work_keys_str_mv | AT kinzasultan casereporthypertriglyceridemiainducedpancreatitisafterlenvatinibandpembrolizumabuse AT ziadkhan casereporthypertriglyceridemiainducedpancreatitisafterlenvatinibandpembrolizumabuse AT siamaksaadat casereporthypertriglyceridemiainducedpancreatitisafterlenvatinibandpembrolizumabuse |